Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEG-Intron maintenance in chronic hepatitis C fibrosis
NCT00049842Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2002
- Primary completion
- Oct 2009
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons
01
Overview
Phase 3, randomised, open-label trial of peginterferon alfa-2b in hepatitis C (HCV) and Liver Fibrosis (LF) (2 arms), sponsored by Merck & Co. Primary endpoint: Fibrosis Response Status (Improvement, No Change, or Worsening) at Month 36. Started Oct 2002; status: completed.
02
Drugs
peginterferon alfa-2b
03
Conditions
hepatitis C (HCV)Liver Fibrosis (LF)
Beyond the preview
Go deeper on NCT00049842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00049842.